A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.
The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).
Inclusion Criteria:
Exclusion Criteria:
Nanjing, 210008, China
Wuhan, 430023, China
Milan, 20162, Italy
Kashiwa-shi, Chiba 277-8577, Japan
Ota-shi, Gunma 373-8550, Japan
Akashi-shi, Hyôgo 673-8558, Japan
Kasama-Shi, Ibaraki 309-1793, Japan
Kita-Gun Miki-Cho, Kagawa-ken 761-0701, Japan
Yokohama-Shi Asahi-Ku, Kanagawa 241-0815, Japan
Chuo-Ku, Kumamoto 860-8556, Japan
Sakyo-ku, Kyoto-shi 606-8507, Japan
Osaki-Shi, Miyagi 989-6136, Japan
Kurashiki-Shi, Okayama-ken 710-0052, Japan
Suita-Shi, Osaka 565-0871, Japan
Takatsuki-Shi, Osaka 569-8686, Japan
Shinjuku-Ku, Tokyo 160-8582, Japan
Lodz, 93-513, Poland
Yenimahalle, 06200, Turkey (Türkiye)
Dnipropetrovsk, 49102, Ukraine